SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Geriatric Psychiatry and Neurology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Demers, L.
Right arrow Articles by Wolfson, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Demers, L.
Right arrow Articles by Wolfson, C.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Alzheimer's Disease
*Genetics Home Reference
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Introduction

Louise Demers, PhD

Mark Oremus, MSc

Anne Perrault, MSc

Christina Wolfson, PhD

This article introduces a four-part series on outcome scales used in Alzheimer's disease drug trials. First, it discusses the division of scales into four domains: cognition, functional ability/quality of life, behavior/mood, and global. Within each domain, the shortcomings of existing literature reviews are outlined, and the need for a more coherent view of the psychometric properties of the scales is emphasized. Second, the key concepts of reliability, validity, and responsiveness to change are defined and explained. This explanation also provides an overview of the statistical techniques used to assess measurement properties. Finally, the methods used to select the scales for review in the subsequent articles are explained, and each article is briefly introduced. (J Geriatr Psychiatry Neurol 2000; 13:161-169).

Journal of Geriatric Psychiatry and Neurology, Vol. 13, No. 4, 161-168 (2000)
DOI: 10.1177/089198870001300401
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
M. Boustani, B. Peterson, L. Hanson, R. Harris, and K. N. Lohr
Screening for Dementia in Primary Care: A Summary of the Evidence for the U.S. Preventive Services Task Force
Ann Intern Med, June 3, 2003; 138(11): 927 - 937.
[Abstract] [Full Text] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
L. Demers, M. Oremus, A. Perrault, N. Champoux, and C. Wolfson
Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Functional and Quality of Life Scales
J Geriatr Psychiatry Neurol, December 1, 2000; 13(4): 170 - 180.
[Abstract] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
A. Perrault, M. Oremus, L. Demers, S. Vida, and C. Wolfson
Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Behavior and Mood Scales
J Geriatr Psychiatry Neurol, December 1, 2000; 13(4): 181 - 196.
[Abstract] [PDF]


Advertisement